fda category 2 bulk drug substances bpc 157 compounding list Big news for peptides! In July, the will meet to evaluate the most commonly used peptides for FDA authorized July 23-24, 2026: Meeting of

[DOI] [PMC free article] [PubMed] [Google Scholar] 170.Kauppinen TM et al

My energy level is fine, nothing crazy, as I was afraid it would be with the B12

Armstrong et al., Reduced physical activity is a common feature of ME/CFS, FM, and GWS

Martnez-Sanz JM, Sospedra I, Ortiz CM, Balada E, Gil- Izquierdo A, Ortiz-Moncada R

A phase III, multinational, randomized parallel-group study (TENERE) was designed as a superiority trial to compare the effectiveness, defined as time to failure (first occurrence of confirmed relapse or permanent treatment discontinuation for any reason, whichever came first), and tolerability of oral teriflunomide 7 mg daily (n=109) or oral teriflunomide 14 mg daily (n=111) versus subcutaneous interferon beta-1a 44 mcg, three times weekly (n=104) (105)

This could be used to help targeting patients with hidden neurorehabilitation needs